Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Trial · NCT01607957
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | TAS-102 | 7.1 | 95% Confidence Interval 6.5 to 7.8 | months | |
| Overall Survival | Placebo | 5.3 | 95% Confidence Interval 4.6 to 6.0 | months | |
| Progression-free Survival | TAS-102 | 2.0 | 95% Confidence Interval 1.9 to 2.1 | months | |
| Progression-free Survival | Placebo | 1.7 | 95% Confidence Interval 1.7 to 1.8 | months | |
| Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths | TAS-102 | Any adverse event (AE) | 98.3 | percentage of participants | |
| Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths | Placebo | Any adverse event (AE) | 93.2 | percentage of participants | |
| Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths | TAS-102 | Any treatment-related AE | 85.7 | percentage of participants | |
| Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths | Placebo | Any treatment-related AE | 54.7 | percentage of participants | |
| Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths | TAS-102 | Any ≥Grade 3 AE | 69.4 | percentage of participants | |
| Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths | Placebo | Any ≥Grade 3 AE | 51.7 | percentage of participants | |
| Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths | TAS-102 | Any treatment-related ≥Grade 3 AE | 49.0 | percentage of participants | |
| Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths | Placebo | Any treatment-related ≥Grade 3 AE | 9.8 | percentage of participants | |
| Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths | TAS-102 | Any serious AE (SAE) | 29.6 | percentage of participants | |
| Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths | Placebo | Any serious AE (SAE) | 33.6 | percentage of participants | |
| Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths | TAS-102 | Any AE resulting in discontinuation | 10.3 | percentage of participants | |
| Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths | Placebo | Any AE resulting in discontinuation | 13.6 | percentage of participants | |
| Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths | TAS-102 | Any AE with outcome of death | 3.2 | percentage of participants | |
| Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths | Placebo | Any AE with outcome of death | 11.3 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01607957/results